Development of malignant hyperthermia during mitral valve replacement

Reed D. Quinn, Walter Pae, Suzan A. McGary, G. Scott Wickey

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Malignant hypothermia is a genetically predisposed, potentially fatal disorder triggered by anesthetic agents. The early diagnosis and treatment of malignant hyperthermia is essential, yet often difficult, because the signs and symptoms of this disorder are not unique to the disease. When the patient is also undergoing cardiopulmonary bypass ihis disorder may be very difficult to recognize. In this article, we report a case of malignant hyperthermia diagnosed during mitral valve replacement and discuss the preoperative and postoperative management possibilities. The unusualness of this case stems from the fact that the patient had centronuclear myopathy. Although reported with other types of myopathies, centronuclear myopathy has rarely been associated with malignant hyperthermia. This episode of malignant hyperthermia was diagnosed by intraoperative measurements showing increased oxygen consumption despite hypothermic cardiopulmonary bypass.

Original languageEnglish (US)
Pages (from-to)1114-1116
Number of pages3
JournalThe Annals of Thoracic Surgery
Volume53
Issue number6
DOIs
StatePublished - Jan 1 1992

Fingerprint

Malignant Hyperthermia
Mitral Valve
Congenital Structural Myopathies
Cardiopulmonary Bypass
Muscular Diseases
Hypothermia
Oxygen Consumption
Signs and Symptoms
Anesthetics
Early Diagnosis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Quinn, Reed D. ; Pae, Walter ; McGary, Suzan A. ; Wickey, G. Scott. / Development of malignant hyperthermia during mitral valve replacement. In: The Annals of Thoracic Surgery. 1992 ; Vol. 53, No. 6. pp. 1114-1116.
@article{368c43d00ba74ce5a15d46a4dbc93b47,
title = "Development of malignant hyperthermia during mitral valve replacement",
abstract = "Malignant hypothermia is a genetically predisposed, potentially fatal disorder triggered by anesthetic agents. The early diagnosis and treatment of malignant hyperthermia is essential, yet often difficult, because the signs and symptoms of this disorder are not unique to the disease. When the patient is also undergoing cardiopulmonary bypass ihis disorder may be very difficult to recognize. In this article, we report a case of malignant hyperthermia diagnosed during mitral valve replacement and discuss the preoperative and postoperative management possibilities. The unusualness of this case stems from the fact that the patient had centronuclear myopathy. Although reported with other types of myopathies, centronuclear myopathy has rarely been associated with malignant hyperthermia. This episode of malignant hyperthermia was diagnosed by intraoperative measurements showing increased oxygen consumption despite hypothermic cardiopulmonary bypass.",
author = "Quinn, {Reed D.} and Walter Pae and McGary, {Suzan A.} and Wickey, {G. Scott}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0003-4975(92)90403-Q",
language = "English (US)",
volume = "53",
pages = "1114--1116",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

Development of malignant hyperthermia during mitral valve replacement. / Quinn, Reed D.; Pae, Walter; McGary, Suzan A.; Wickey, G. Scott.

In: The Annals of Thoracic Surgery, Vol. 53, No. 6, 01.01.1992, p. 1114-1116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of malignant hyperthermia during mitral valve replacement

AU - Quinn, Reed D.

AU - Pae, Walter

AU - McGary, Suzan A.

AU - Wickey, G. Scott

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Malignant hypothermia is a genetically predisposed, potentially fatal disorder triggered by anesthetic agents. The early diagnosis and treatment of malignant hyperthermia is essential, yet often difficult, because the signs and symptoms of this disorder are not unique to the disease. When the patient is also undergoing cardiopulmonary bypass ihis disorder may be very difficult to recognize. In this article, we report a case of malignant hyperthermia diagnosed during mitral valve replacement and discuss the preoperative and postoperative management possibilities. The unusualness of this case stems from the fact that the patient had centronuclear myopathy. Although reported with other types of myopathies, centronuclear myopathy has rarely been associated with malignant hyperthermia. This episode of malignant hyperthermia was diagnosed by intraoperative measurements showing increased oxygen consumption despite hypothermic cardiopulmonary bypass.

AB - Malignant hypothermia is a genetically predisposed, potentially fatal disorder triggered by anesthetic agents. The early diagnosis and treatment of malignant hyperthermia is essential, yet often difficult, because the signs and symptoms of this disorder are not unique to the disease. When the patient is also undergoing cardiopulmonary bypass ihis disorder may be very difficult to recognize. In this article, we report a case of malignant hyperthermia diagnosed during mitral valve replacement and discuss the preoperative and postoperative management possibilities. The unusualness of this case stems from the fact that the patient had centronuclear myopathy. Although reported with other types of myopathies, centronuclear myopathy has rarely been associated with malignant hyperthermia. This episode of malignant hyperthermia was diagnosed by intraoperative measurements showing increased oxygen consumption despite hypothermic cardiopulmonary bypass.

UR - http://www.scopus.com/inward/record.url?scp=0026720997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026720997&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(92)90403-Q

DO - 10.1016/0003-4975(92)90403-Q

M3 - Article

VL - 53

SP - 1114

EP - 1116

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -